colon cancer
Conditions
Interventions
Liposomal Bupivacaine group:Liposomal Bupivacaine TAP Block
266 mg liposomal bupivacaine (20 mL) diluted with 10 mL normal saline to a total volume of 30 mL.
Bupivacaine hydrochloride group :100 mg of bupivacaine hydrochloride was diluted to 30 mL and administered preoperatively as bilateral transversus abdominis plane (TAP) blocks, with 15 mL per side.
Sponsors
Affiliated Hospital of Jiangnan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) ASA physical status I–III. (2) Age 18–65 years. (3) Body mass index (BMI) 18–30 kg/m².
Exclusion criteria
Exclusion criteria: (1) Infection at the puncture site; (2) History of long-term analgesic use or allergy to local anesthetics or any investigational drugs; (3) Coagulopathy (or Coagulation disorders); (4) Severe comorbidities involving the cardiovascular, cerebrovascular, respiratory, immune, or central nervous systems, or hepatic/renal impairment; (5) Pregnancy or active pregnancy planning; (6) Refusal to participate in this clinical study; (7) Local anesthetic allergy; (8) Psychiatric or neurological disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative Pain Assessment (2–72 Hours): Resting NRS Pain Score AUC; | — |
Secondary
| Measure | Time frame |
|---|---|
| 15-Item Quality of Recovery Scale (QoR-15) for Postoperative Recovery Assessment at 72 Hours;PCIA Press Count and Total Analgesic Consumption;PONV and Pruritus and Respiratory Depression;Time to First Postoperative Ambulation;length of hospital stay;NRS pain scores at rest and during movement at 2h, 6h, 12h, 24h, 48h, and 72h postoperatively in both patient groups; | — |
Countries
China
Contacts
Public ContactZhangjun Zhang
Affiliated Hospital of Jiangnan University
Outcome results
None listed